Unilife had to spend lots of cash and hire lots of people to fast-track the Unifill program, getting it ready for sale. They crammed a typical six year program into less than half that time. If they had not done it, they would never sell a single prefilled syringe as pharmas want to see the capacity and quality levels before they commit to you being the drug container (which is a big deal). So that chapter - read operational surge - is now complete.
Now it's time for a new focus. So they are getting rid of a lot of folks in areas like engineering that aren't needed any more. And they are replacing them with sales and marketing people who can do pharma deals for the Unifill syringe, and others who can go and finalize designs for the next generation of cool products (that pharma will also pay upfront cash for to help bring to market).
All up, the new focus comes down to two things. Sales of the Unifill, and exciting deals with as many pharma companies as possible, for as many products as possible. The Unitract 1mL is not going away. It's still there. But it hasnt been the priority for a long time. But any previously budgeteted item which doesn't fit the criteria of sales, pharma deals or developing cool new products is either now gone or deferred. They can now be better focused. Their systems can now be streamlined. They can be more efficient in their use of cash.
UNS Price at posting:
81.0¢ Sentiment: LT Buy Disclosure: Held
